TREATMENT OPTIONS FOR METASTATIC NON-SMALL CELL LUNG CANCER WITH ROS1 GENE TRANSLOCATION BY TYROSINE KINASE INHIBITORS

Abstract

ROS1 (c-ros oncogene 1, receptor tyrosine kinase) rearrangements occur in 1–4% of patients with non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitor (TKI) is recommended in the first-line setting in patients with metastatic NSCLC with ROS1 and ALK (anaplastic lymphoma receptor tyrosine kinase) rearrangements. Crizotinib is an oral, first-generation ALK, ROS1 and MET receptor TKI, which become the first-line treatment in patients with ALK-positive metastatic NSCLC. In PROFILE 1001 trial, the population of ROS1-positive patients, who had administered Crizotinib, median objective survival was more than 4 years. Crizotinib is also safe for long-term administration; thus, possible side effects are short-term.